Investor Relations

Latest News

ASP Isotopes Inc. Responds To Short Seller “Report”

Read Press Release

ASP Isotopes Inc. to host Investor Access Event in South Africa from January 14-16, 2025

Read Press Release

ASP Isotopes Inc. Responds to Short Seller Report

Read Press Release

Latest Presentation

Company Presentation

Upcoming Event

Investor Access Event

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

ASP is an advanced materials company dedicated to developing technology and processes designed to produce and enrich isotopes used in multiple markets, which include Nuclear Medicine and therapeutics, green energy generation, and quantum computing.

Our initial focus is to utilize our proprietary ASP technology to construct, commission, and later produce commercial amounts of highly enriched isotopes for the Nuclear medicine market at our plants located in South Africa. We believe that the isotopes we may develop using the ASP technology have significant potential advantages to the end user, as well as commercial advantages due to companies’ Modular, cost-effective, and environmentally friendly processes.

We may also seek to use the ASP technology to separate other isotopes in the future, which we believe have potential applications in the quantum computing target end market and nuclear green energy end market.

We were incorporated in Delaware in September 2021. Our principal executive offices are located at 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004, and our website address is www.aspisotopes.com.

Stock Snapshot

IR Contacts

Headquarters

ASP Isotopes Inc.
601 Pennsylvania Avenue NW
South Building, Suite 900
Washington, DC 20004
United States

Investor Relations

Jason Assad
T: 561-709-3043
Jassad@aspisotopes.com

Transfer Agent

Equiniti Trust Company LLC
PO Box 500
Newark, NJ 07101
United States
T: 800-937-5449 (US), 718-921-8124 (Int’l)
helpAST@equiniti.com